Sanofi/Regeneron’s IL-33 blocker mee...Sanofis and Regenerons IL-33 blocker REGN3500 met primary Phase II endpoint in asthma patients. more ➔
Karo Pharma acquires Trimb ABKaro Pharma AB announced it will acquire Trimb Holding AB for MSEK3,400 (€319.6m) and intends to carry out a Rights Issue of about MSEK 1,500 (€141m). more ➔
UK biotech to make proteins from carbon di...Deep Branch Biotechnology Ltd. from Nottingham has started a feasibility study with the British energy supplier Drax Group. The technology to be analysed converts carbon dioxide emitted by power … more ➔
GM proponents grill German governmentGerman GM proponents have taken action against discrimination of food products generated by gene editing. more ➔
Human cell chip predicts chemotherapy effe... Roche and US company Hesperos Inc have used human cancer and organ cells, placed in a 5-chamber microfluidic chip, to predict chemotherapy safety and efficacy preclinically. more ➔
IL-10R-deficient macrophages trigger IBDResearchers from Israel and the UK have identified how the cytokine IL-23 triggers inflammatory bowel syndrome (IBD), which affects 1.6 million patients annually in the US alone. more ➔
Breakthrough in liquid biopsy German and US researchers have developed a diagnostic technique capable to detect one single circulating tumour cell in one litre of blood. more ➔
ADC Therapeutics raise $76m in Series E ex...Swiss antibody drug conjugate developer ADC Therapeutics SA raised $76m, bringing the total gross proceeds to $276 million in its Series E financing. more ➔
Janssen and Genmab in licence option dealJanssen Biotech Inc has inked a licence option contract with Genmab A/S on its next-generation anti CD38 antibody HexaBody®-CD38 and HexaBody platform technology. more ➔
Evotec bags US$23.8m to fight tuberculosis The Bill & Melinda Gates Foundation has granted Evotec SE $23.8m to identify the best drug combos to fight tuberculosis. more ➔
